as 07-26-2024 4:00pm EST
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Founded: | 2016 | Country: | United States |
Employees: | N/A | City: | IRVINE |
Market Cap: | 1.1B | IPO Year: | 2020 |
Target Price: | $50.83 | AVG Volume (30 days): | 759.9K |
Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -4.73 | EPS Growth: | N/A |
52 Week Low/High: | $12.57 - $42.50 | Next Earning Date: | 08-08-2024 |
Revenue: | $42,561,000 | Revenue Growth: | 53.22% |
Revenue Growth (this year): | 733.61% | Revenue Growth (next year): | 82.78% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Farrow Jeffrey S | TARS | See Remarks | Jun 17 '24 | Sell | $27.47 | 10,445 | $286,924.15 | 18,136 | SEC Form 4 |
Wahl Bryan | TARS | General Counsel | Mar 15 '24 | Sell | $30.60 | 4,436 | $135,741.60 | 40,951 | SEC Form 4 |
Whitfield Dianne C. | TARS | Chief Human Resources Officer | Mar 15 '24 | Sell | $30.60 | 4,314 | $132,008.40 | 34,181 | SEC Form 4 |
Neervannan Seshadri | TARS | Chief Operating Officer | Mar 15 '24 | Sell | $30.60 | 4,879 | $149,297.40 | 64,767 | SEC Form 4 |
Mottiwala Aziz | TARS | Chief Commercial Officer | Mar 15 '24 | Sell | $30.60 | 4,766 | $145,839.60 | 54,075 | SEC Form 4 |
Azamian Bobak R. | TARS | President/CEO and Board Chair | Mar 15 '24 | Sell | $30.60 | 10,415 | $318,699.00 | 26,456 | SEC Form 4 |
Azamian Bobak R. | TARS | President/CEO and Board Chair | Dec 27 '23 | Sell | $20.22 | 8,000 | $161,760.00 | 830,106 | SEC Form 4 |
Trevejo Jose M. | TARS | CHIEF MEDICAL OFFICER | Dec 20 '23 | Sell | $20.00 | 2,252 | $45,040.00 | 2,251 | SEC Form 4 |
Azamian Bobak R. | TARS | President/CEO and Board Chair | Dec 20 '23 | Sell | $19.96 | 9,443 | $188,482.28 | 868,663 | SEC Form 4 |
Azamian Bobak R. | TARS | President/CEO and Board Chair | Dec 20 '23 | Sell | $20.36 | 30,557 | $622,140.52 | 838,106 | SEC Form 4 |
Goldberg Andrew D. | TARS | Director | Dec 15 '23 | Buy | $18.96 | 1,000 | $18,960.00 | 3,000 | SEC Form 4 |
Whitfield Dianne C. | TARS | Chief Human Resources Officer | Nov 29 '23 | Sell | $16.31 | 8,355 | $136,270.05 | 26,784 | SEC Form 4 |
Wahl Bryan | TARS | General Counsel | Nov 29 '23 | Sell | $16.31 | 8,356 | $136,286.36 | 31,966 | SEC Form 4 |
Azamian Bobak R. | TARS | President/CEO and Board Chair | Nov 15 '23 | Sell | $18.01 | 2,896 | $52,156.96 | 883,210 | SEC Form 4 |
Azamian Bobak R. | TARS | President/CEO and Board Chair | Nov 15 '23 | Sell | $18.54 | 4,904 | $90,920.16 | 878,306 | SEC Form 4 |
Azamian Bobak R. | TARS | President/CEO and Board Chair | Nov 15 '23 | Sell | $19.28 | 200 | $3,856.00 | 878,106 | SEC Form 4 |
TARS Breaking Stock News: Dive into TARS Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 days ago
PR Newswire
2 months ago
Business Wire
2 months ago
Business Wire
2 months ago
Reuters
2 months ago
Investor's Business Daily
2 months ago
Business Wire
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "TARS Tarsus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.